Evidence map›Paper›PMID 30726946›Full record

Observational studyJournal of the National Cancer Institute2019

Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).

Vicente Morales-Oyarvide, Chen Yuan, Ana Babic, Sui Zhang, Donna Niedzwiecki, Jennie C Brand-Miller, Laura Sampson-Kent, Xing Ye, Yanping Li, Leonard B Saltz and 17 more

Abstract readObservational Study
In one paragraph

Observational study in Journal of the National Cancer Institute, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Insulin and cancer: a tangled web.The Biochemical journal · 2022
    Review
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Vicente Morales-OyarvideDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Chen YuanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Ana BabicDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Sui ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Donna NiedzwieckiAlliance Statistics and Data Center, Duke University, Durham, NC.
Jennie C Brand-MillerInstitute of Obesity, Nutrition, and Exercise, University of Sydney, Sydney, Australia.
Laura Sampson-KentDepartment of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA.
Xing YeAlliance Statistics and Data Center, Duke University, Durham, NC.
Yanping LiDepartment of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA.
Leonard B SaltzMemorial Sloan Kettering Cancer Center, New York, NY.
Robert J MayerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Rex B MowatToledo Community Hospital Oncology Program, Toledo, OH.
Renaud WhittomHôpital du Sacré-Coeur de Montréal, Montreal, Canada.
Alexander HantelLoyola University Stritch School of Medicine, Naperville, IL.
Al BensonRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
Daniel AtienzaVirginia Oncology Associates, Norfolk, VA.
Michael MessinoSoutheast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC.
Hedy KindlerUniversity of Chicago Comprehensive Cancer Center, Chicago, IL.
Alan VenookUniversity of California at San Francisco Comprehensive Cancer Center, San Francisco, CA.
Shuji OginoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Kana WuDepartment of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA.
Walter C WillettDepartment of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA.
Edward L GiovannucciDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA.
Brian M WolpinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Jeffrey A MeyerhardtDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Charles S FuchsYale Cancer Center, Smilow Cancer Hospital and Yale School of Medicine, New Haven, CT.
Kimmie NgDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2M
SOUTHEAST CANCER CONTROL COSORTIUM, INCU10CA045808 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI ATKINS, JAMES NORMAN · 1987 to 2013
$26.6M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareU10CA180867 · NCI · DANA-FARBER CANCER INST · PI BURSTEIN, HAROLD JOHN, KIBEL, ADAM S · 2014 to 2018
$6.2M
Accelerating Transdisciplinary Epidemiology of Colorectal CancerR35CA197735 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2015 to 2021
$6.0M
CANCER &LEUKEMIA GROUP BU10CA032291 · NCI · DANA-FARBER CANCER INSTITUTE · PI BURSTEIN, HAROLD J. · 1985 to 2013
$5.8M
NCI NIH HHS K07 CA148894NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA118553NCI NIH HHS R01 CA149222NCI NIH HHS R01 CA169141NCI NIH HHS R01 CA205406NCI NIH HHS R35 CA197735NCI NIH HHS U10 CA032291NCI NIH HHS U10 CA041287NCI NIH HHS U10 CA045808NCI NIH HHS U10 CA077651NCI NIH HHS U10 CA138561NCI NIH HHS U10 CA180791NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180836NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA189974NCI NIH HHS UG1 CA233180
6 · The paper itself

Abstract

backgroundEvidence suggests that diets inducing postprandial hyperinsulinemia may be associated with increased cancer-related mortality. The goal of this study was to assess the influence of postdiagnosis dietary insulin load and dietary insulin index on outcomes of stage III colon cancer patients.

methodsWe conducted a prospective observational study of 1023 patients with resected stage III colon cancer enrolled in an adjuvant chemotherapy trial who reported dietary intake halfway through and six months after chemotherapy. We evaluated the association of dietary insulin load and dietary insulin index with cancer recurrence and survival using Cox proportional hazards regression adjusted for potential confounders; statistical tests were two-sided.

resultsHigh dietary insulin load had a statistically significant association with worse disease-free survival (DFS), comparing the highest vs lowest quintile (adjusted hazard ratio [HR] = 2.77, 95% confidence interval [CI] = 1.90 to 4.02, Ptrend < .001). High dietary insulin index was also associated with worse DFS (highest vs lowest quintile, HR = 1.75, 95% CI = 1.22 to 2.51, Ptrend= .01). The association between higher dietary insulin load and worse DFS differed by body mass index and was strongest among patients with obesity (HR = 3.66, 95% CI = 1.88 to 7.12, Pinteraction = .04). The influence of dietary insulin load on cancer outcomes did not differ by mutation status of KRAS, BRAF, PIK3CA, TP53, or microsatellite instability.

conclusionsPatients with resected stage III colon cancer who consumed a high-insulinogenic diet were at increased risk of recurrence and mortality. These findings support the importance of dietary management following resection of colon cancer, and future research into underlying mechanisms of action is warranted.

Indexed as

Colonic NeoplasmsDietHyperinsulinismHypoglycemic AgentsInsulinNeoplasm Recurrence, LocalAdultAgedAged, 80 and overCase-Control StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingHypoglycemic AgentsInsulin

Identifiers

PMID30726946
PMCPMC6376913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.